Category: 3. Business

  • StanChart’s Global Head of Fixed Income Research Rudra Retires

    StanChart’s Global Head of Fixed Income Research Rudra Retires

    Kaushik Rudra, global head of fixed-income research at Standard Chartered Plc, has retired after 17 years at the bank, according to a company email.

    Becky Liu and Gordian Kemen will co-head emerging-markets rates research and strategy following Rudra’s departure, according to the email. Liu was head of China macro strategy in Hong Kong and Kemen was head of emerging markets sovereign strategy.

    Continue Reading

  • "MiCA reaches its six-month milestone: early takeaways and challenges ahead" – BBVA

    "MiCA reaches its six-month milestone: early takeaways and challenges ahead" – BBVA

    1. “MiCA reaches its six-month milestone: early takeaways and challenges ahead”  BBVA
    2. Tether CEO Criticizes MiCA as a ‘Gift to Banks’  ForkLog
    3. Coinbase Price Sentiment Boosted as Exchange Adopts MiCAR-Compliant White Papers for EU  The Tradable
    4. Circle Secures First MiCA-Compliant Stablecoin License  ForkLog

    Continue Reading

  • Powell's last Jackson Hole speech could pack a punch – Reuters

    1. Powell’s last Jackson Hole speech could pack a punch  Reuters
    2. Federal Reserve Bank of Kansas City to Host Annual Jackson Hole Economic Policy Symposium Aug. 21-23  Kansas City – Federal Reserve
    3. Jay Powell to deliver Jackson Hole address under fire on multiple fronts  Financial Times
    4. Which sectors will fall if the Fed delivers a hawkish surprise at Jackson Hole?  Investing.com
    5. US 10-Year Yield Inches Down  TradingView

    Continue Reading

  • India’s biofuel drive is saving billions but also sparking worries

    India’s biofuel drive is saving billions but also sparking worries

    Getty Images A petrol pump worker, in a saffron dress, putting fuel in a bike. The pumping machine can be seen in the background.

Getty Images

    Indian government says ethanol blending has cut 69.8 million tonnes of carbon dioxide emissions since 2014

    India’s drive to blend more biofuels with petrol has helped the country cut millions of tonnes of carbon dioxide emissions and save precious dollar reserves.

    But it has also sparked worries among vehicle owners and food policy experts about its potential impact on fuel efficiency and food security.

    Last month, India achieved its objective of blending 20% ethanol with petrol, known as E20, five years ahead of its target.

    The government views this as a game changer in reducing carbon emissions and trimming oil imports. Since 2014, ethanol blending has helped India cut 69.8 million tonnes of carbon dioxide emissions and saved 1.36 trillion rupees ($1.5 bn; £1.1 bn) in foreign exchange.

    A study by Delhi-based think tank Council on Energy, Environment and Water (CEEW) shows that carbon dioxide emissions from road transport in India will nearly double by 2050.

    “The demand for fuel is only going to increase and shifting to ethanol-blended petrol is absolutely necessary to cut down emissions,” Sandeep Theng from the Indian Federation of Green Energy, an organisation that promotes green energy, told the BBC.

    But many vehicles in India are not E20-compliant, making their owners sceptical about the benefits of the policy.

    Hormazd Sorabjee, editor of Autocar India magazine, said that ethanol has a “lower energy density than petrol and is more corrosive”. This results in lower mileage and exposes certain vehicle parts to a greater risk of wear and tear.

    Mr Sorabjee added that some manufacturers like Honda have been using E20 compliant material since 2009, but many older vehicles on Indian roads are not E20 compatible.

    While there is no official data on the impact of of E20 fuel on engines, consumers routinely share anecdotes about their vehicle’s deteriorating mileage on social media.

    Many standard insurance policies in India also don’t provide cover for damage due to the use of non-compliant fuel, a top executive at online insurance platform Policybazaar, who wanted to stay anonymous, told the BBC.

    “Consumers need to take add-on policies but even those claims can be denied or downgraded based on fine print of the policy,” he added.

    The federal petroleum ministry has described these concerns as “largely unfounded”.

    In a post on X, the ministry said that engine tuning and E20-compatible materials could minimise the drop in mileage. It also advised replacing certain parts in older vehicles, saying the process was inexpensive and “easily done during regular servicing of the vehicle”.

    Getty Images A worker, wearing turquoise-white checked shirt and blue jeans, inside a factory, working with stubble. 
Getty Images

    Expansion of ethanol use could mean diverting more farm produce into manufacturing fuel

    Mr Sorabjee told the BBC that while milage concerns are real, they are a “not always as bad as made out to be”.

    The bigger concern, he said, was the potential damage to vehicle materials due to the corrosive properties of E20.

    Some vehicle manufacturers are offering ways to mitigate this.

    Maruti Suzuki, India’s biggest four-wheeler maker, is reportedly likely to introduce an E20 material kit that could cost up to 6,000 rupees ($69; £51). The kit will reportedly replace components like fuel lines, seals and gaskets. Bajaj, a leading Indian two-wheeler maker, has advised using a fuel cleaner that could cost around 100 rupees ($1.15; £0.85) for a full tank of petrol.

    But not all vehicle-owners are convinced. Amit Pandhi, who has owned a Maruti Suzuki car in Delhi since 2017, is unhappy that petrol pumps don’t offer the choice to opt for a blend other than E20.

    “Why should I be forced to buy petrol that offers less mileage and then spend more to make the materials compliant?” he asked.

    In 2021, a document on India’s transition to E20 published by Niti Aayog, a government think tank, had highlighted some of these concerns. It recommended tax benefits for buying E20 compliant vehicles, along with a lower retail price for the fuel.

    The government has defended its decision to not pass the recommendations, saying that at the time of the report’s relase, ethanol was cheaper than petrol.

    “Over time, procurement price of ethanol has increased and now the weighted average price of ethanol is higher than cost of refined petrol,” the petroleum ministry said earlier this month.

    Getty Images India's federal Minister of Petroleum and Natural Gas Hardeep Singh Puri, wearing blue jacket and turban, with his hand raised, is addressing a gathering. Getty Images

    India is looking to increase ethanol-blending in petrol in the coming years

    It’s not just consumers – the government’s blended fuel push has also raised concern among climate researchers and food policy experts.

    Ethanol is produced from crops like sugarcane and maize, and expanding its use means diverting farm produce into manufacturing more fuel.

    In 2025, India would need 10 billion litres of ethanol to meet its E20 requirements, according to government estimates. The demand will balloon to 20 billion litres by 2050, according to Bengaluru-based think tank Center for Study of Science, Technology and Policy (CSTEP).

    Right now, sugarcane is used to produce about 40% of India’s ethanol.

    This puts India in a bind. It has to choose between continuing its reliance on sugarcane – which has a higher yield for ethanol but is water-intensive – or using food crops like maize and rice to produce the fuel.

    But the shift comes with its own challenges.

    In 2024, for the first time in decades, India became a net importer of maize, using large amounts of the crop to make ethanol.

    Ramya Natarajan, a research scientist at CSTEP, said the diversion of produce had a significant impact on the poultry sector, which now has to spend more to buy corn for feedstock.

    Moreover, this year, the Food Corporation of India (FCI) approved an unprecedented allocation of 5.2 million tonnes of rice for ethanol production. The rice in FCI stocks is earmarked to be given to India’s poor at a subsidised rate.

    The policy could lead to an “agriculture disaster in a couple of years”, said Devinder Sharma, a farming sector expert.

    “In a country like India, where 250 million people go hungry, we cannot use food to feed the cars,” Mr Sharma said.

    To meet the demand for ethanol through corn and sugarcane in a 50-50 ratio – as outlined by Niti Aayog – India would have to bring in an additional eight million hectares of land under maize cultivation by 2030, unless there is a drastic increase in yield, according to CSTEP.

    But even that could lead to problems.

    “If farmers replace rice or wheat cultivation with maize, that would be sustainable because we have enough surplus of these crops. But we need other crops like oilseeds and pulses too,” Ms Natarajan said.

    Ms Natarajan added that continuing with the E10 blend – petrol mixed with 10% ethanol – would have been a more ideal choice.

    India, however, is planning to go even beyond E20.

    “The country will now gradually scale towards E25, E27, and E30 in a phased, calibrated manner,” Petroleum Minister Hardeep Puri said recently.

    Follow BBC News India on Instagram, YouTube, X and Facebook


    Continue Reading

  • Strong commercial performance enables investment for long-term growth

    Strong commercial performance enables investment for long-term growth

    Telix Therapeutics: Reinvesting earnings to accelerate late-stage pipeline

    Of the total R&D investment, 54% ($43.9 million) was invested in the therapeutics pipeline. Milestones achieved include:

    • TLX591 (177Lu-rosopatamab tetraxetan): Completed target enrollment of 30 patients for Part 1 of the Phase 3 study in advanced metastatic castration resistant prostate cancer (mCRPC). The trial has received regulatory approval to proceed in Australia, China, Canada, New Zealand, Turkey and Japan.

    • TLX592 (225Ac-PSMA-RADmAb): Approval to commence a Phase 1, first-in-human therapeutic study of a targeted alpha therapy in advanced mCRPC.

    • TLX101 (131I-iodofalan, or 131I-IPA): Approval to commence IPAX BrIGHT, an international pivotal trial, to commence at Australian sites initially.

    • TLX090 (153Sm-DOTMP): Investigational New Drug (IND) application approved for a Phase 1 bridging study for Telix’s therapeutic candidate for the palliation of bone pain in patients with osteoblastic metastatic disease to the bone.

    Commentary

    Managing Director and Group CEO, Dr. Christian Behrenbruch, commented on the result:

    “Telix continues to deliver strong revenue growth while building a foundation for the future. The first half of 2025 was a period of rapid transformation as we expanded our global manufacturing operations, invested in launching new products in new markets, and accelerated the development of our therapeutic pipeline. These investments have positioned Telix for sustainable, long-term growth, while our diversified business provides multiple drivers of success. To generate future revenue growth, we are confident in securing product approvals for Pixclara and Zircaix while advancing geographic and indication expansion for the PSMA portfolio.”

    Summary Group financial results

     

    H1 2025

    H1 2024

     

    US$M

    US$M

    Revenue

    390.4

     

    239.6

     

    Cost of sales

    (181.8

    )

    (82.4

    )

    Gross profit

    208.6

     

    157.2

     

    Research and development (R&D)

    (81.6

    )

    (55.4

    )

    Selling and marketing

    (49.0

    )

    (24.6

    )

    Manufacturing and distribution

    (18.8

    )

    (8.4

    )

    General and administration

    (47.7

    )

    (39.2

    )

    Other losses (net)

    (1.1

    )

    (1.9

    )

    Operating profit

    10.4

     

    27.7

     

    Finance income

    3.6

     

    0.9

     

    Finance costs

    (18.8

    )

    (5.7

    )

    (Loss)/profit before tax

    (4.8

    )

    22.9

     

    Adjusted EBITDA

    21.1

     

    37.1

     

    Cash from operating activities

    17.7

     

    23.3

     


    Guidance

    • Telix confirms FY 2025 revenue guidance of US$770 million to US$800 million11.

    • Guidance reflects revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS12.

    • Telix confirms R&D expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024.

    lnvestor call

    An investor webcast and conference call will be held at 9.30am AEST on Thursday 21 August 2025 (7.30pm EDT Wednesday 20 August 2025).

    Participants can register for the webcast by clicking here: https://edge.media-server.com/mmc/p/x4gytx8w/ or the teleconference here: https://s1.c-conf.com/diamondpass/10049152-x745re.html

    About Telix Pharmaceuticals Limited

    Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, United Kingdom, Canada, Europe (Belgium and Switzerland), Brazil and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

    Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

    Telix Investor Relations (Global)

    Ms. Kyahn Williamson
    Telix Pharmaceuticals Limited
    SVP Investor Relations and Corporate Communications
    Email: kyahn.williamson@telixpharma.com

    Telix Investor Relations (U.S.)

    Ms. Annie Kasparian
    Telix Pharmaceuticals Limited
    Director Investor Relations and Corporate Communications
    Email: annie.kasparian@telixpharma.com

    Guidance Disclaimer

    The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

    Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property.

    This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors

    Legal Notices

    Cautionary Statement Regarding Forward-Looking Statements.

    You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

    The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

    This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context
    of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

    Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

    ©2025 Telix Pharmaceuticals Limited. All rights reserved.

    1. See summary Group financial results table at end of this document.

    2. Group performance includes Telix Precision Medicine, Telix Therapeutics and Telix Manufacturing Solutions (TMS).

    3. All comparisons to H1 2024 results.

    4. FY 2025 revenue guidance of US$770 million to US$800 million.

    5. Earnings before interest, tax, depreciation and amortization.

    6. Increased investment range for FY 2025 expected to be 20% to 25% compared to FY 2024.

    7. Launch and brand names subject to final regulatory approval.

    8. RLS network is comprised of 28 locations across the U.S.

    9. Positron emission tomography.

    10. Single photon emission computed tomography.

    11. Refer to ASX disclosures 20 February 2025.

    12. See Guidance Disclaimer for further information.

    Continue Reading

  • Beijing turns against Nvidia’s AI chip after ‘insulting’ Lutnick remarks

    Beijing turns against Nvidia’s AI chip after ‘insulting’ Lutnick remarks

    Beijing’s move to restrict sales of Nvidia’s China-specific artificial intelligence processor was prompted by remarks from US commerce secretary Howard Lutnick about chip exports that officials found “insulting”.

    A group of Chinese regulators have mobilised in an effort to dissuade domestic tech companies from acquiring the H20 — a watered-down processor widely used for artificial intelligence in China.

    According to people with knowledge of the regulatory action, the Cyberspace Administration of China (CAC), the National Development and Reform Commission (NDRC) and the Ministry of Industry and Information Technology (MIIT) moved in response to comments made by Lutnick last month.

    “We don’t sell them our best stuff, not our second-best stuff, not even our third-best,” Lutnick told CNBC on July 15, the day after the Trump administration lifted export controls, implemented in April, on H20 sales.

    “You want to sell the Chinese enough that their developers get addicted to the American technology stack, that’s the thinking,” he added.

    Some of China’s senior leaders found the comments “insulting”, leading to the policymakers to seek ways to restrict Chinese tech firms from buying the processors, according to two people with knowledge of the latest regulatory decision-making.

    As a result, Chinese tech groups held off or significantly downsized their H20 orders, according to those with knowledge of their plans.

    The moves have come as a blow to Nvidia, whose chief executive Jensen Huang last month visited Beijing and committed to stay competitive in the country despite growing geopolitical tensions with the US.

    Following Huang’s warmly received trip, Nvidia received sufficient interest from Chinese clients that it told fabrication partner TSMC to reopen its H20 production lines, according to two people with knowledge of the matter.

    Chinese regulators have urged more use of domestic chips in recent years, but tech giants from Alibaba to ByteDance argued that their AI development would be impaired without Nvidia’s chips, hurting China’s chance to win the technology arms race with the US.

    However, some close to the tech companies said they have now become more accepting of a switch, especially for “inference”, in which AI systems respond to requests from users.

    That shift came after testing and adopting chips from domestic producers led by Huawei and Cambricon at a larger scale, following Washington’s initial April ban on exporting Nvidia’s H20s. 

    “Lutnick’s speech gives the coalition [of regulators] one more reason to intensify its efforts to push tech firms to use China’s own chips,” said a person close to the policymakers.

    A week after his comments, China’s internet regulator CAC issued so-called “window guidance” — an informal notice — to major tech firms such as ByteDance and Alibaba, citing security concerns and instructing them to halt new orders for Nvidia’s H20 chips, according to people with knowledge of the regulator’s effort.

    On July 31, the agency summoned Nvidia executives over alleged “serious security issues”. In a statement, the CAC claimed that US AI experts had revealed Nvidia’s chips have location tracking and can be shut down remotely — a claim strongly disputed by Nvidia.

    MIIT, China’s regulator of telecoms and software, also spoke with Chinese tech executives informally to echo CAC’s stance, according to one of the people with knowledge of the meetings.

    The NDRC, China’s state planner that is in charge of the country’s drive for tech independence, then issued its own window guidance, requesting that tech firms refrain from purchasing all Nvidia chips, including the H20, said those with knowledge of the move.

    NDRC has been for years tasked with promoting chip independence and helping domestic players such as Huawei to capture market share from Nvidia.

    The new involvement of CAC in particular has created more pressure for Chinese tech giants to comply, even if the instructions remain informal, as any potential penalties from the watchdog would choke their daily operations.

    These actions are in sharp contrast to other Chinese departments, such as the commerce and foreign affairs ministries, which have been more open to Nvidia’s business, according to industry insiders.

    The two ministries, which are also in charge of trade negotiations with the US, welcomed Huang in July as a positive signal for foreign businesses and to show Beijing’s goodwill in the ongoing trade talks, the people said.

    “A lot of uncertainties remain depending on trade negotiations and Washington’s next moves,” said one of the people. “The fact that all current restrictive guidance from various regulators remain informal provides some room for future changes.”

    Despite some Washington officials and lawmakers seeking stronger chip curbs, President Trump has said he could potentially allow a downgraded Nvidia Blackwell chip to be exported to China in addition to H20.

    Some Chinese tech companies have held off their H20 orders also because they want see if the China specific Blackwell chip, which potentially has better performance than H20, would become available, according to people with knowledge of their thinking.

    Some Beijing policymakers are pushing to ban foreign chips altogether for inference, which accounts for most AI demand, according to a person recently summoned for a meeting with them.

    That is unlikely to happen soon due to a shortage of domestic chip supplies, which Beijing hopes to significantly improve by next year when several advanced production lines are scheduled to launch.

    China’s foreign ministry said: “As a matter of principle, science, technology, and economic and trade issues should not be politicised, instrumentalised, or weaponised. Containment and suppression will not hold back China’s development.”

    Other Chinese regulators and ministries did not respond to questions for comment. Alibaba and ByteDance did not answer emails requesting comment. The US Commerce department did not immediately respond to a request for comment. Nvidia declined to comment.

    Additional reporting from Michael Acton in San Francisco and Eleanor Olcott in Beijing

    Continue Reading

  • Fed’s Cook Says She Won’t Be Bullied Into Stepping Down

    Fed’s Cook Says She Won’t Be Bullied Into Stepping Down

    Federal Reserve Governor Lisa Cook signaled her intention to remain at the central bank, defying calls for her resignation by President Donald Trump over allegations of mortgage fraud.

    “I have no intention of being bullied to step down from my position because of some questions raised in a tweet,” Cook said in an emailed statement via a Fed spokesperson. “I do intend to take any questions about my financial history seriously as a member of the Federal Reserve and so I am gathering the accurate information to answer any legitimate questions and provide the facts.”

    Continue Reading

  • Asia markets mostly rise as investors assess S&P 500’s four-day losing streak

    Asia markets mostly rise as investors assess S&P 500’s four-day losing streak

    Evening view of Marine Drive, Queen’s necklace, Juhu and Chowpatty beaches

    Grant Faint | The Image Bank | Getty Images

    Asia-Pacific markets mostly rose as investors assessed the four-day losing streak for the S&P 500, led by declines in tech stocks.

    Investors in the region are awaiting India’s HSBC Composite flash purchasing managers’ index reading for August, which provides an early snapshot of the performance of the private sector economy, expected later in the day. Economists polled by Reuters expect it to come in at 60.5, compared with 61.1 in the month before.

    Japan’s Nikkei 225 was down 0.21% in early trade, while the broader Topix index ticked down 0.4%.

    In South Korea, the Kospi index rose 0.81%, while the small-cap Kosdaq increased by 0.62%.

    Australia’s S&P/ASX 200 benchmark started the day 0.47% higher.

    Hong Kong’s Hang Seng index is slated to open flat with futures tied to the index at 25,168, compared with the HSI’s last close of 25,165.94.

    U.S. equity futures were little changed in early Asia hours.

    Overnight stateside, two of the three key benchmarks ended the session in declines as tech stocks dragged the market lower.

    The broad market S&P 500 index slipped 0.24% to close at 6,395.78, while the tech-heavy Nasdaq Composite lost 0.67% and settled at 21,172.86. Wednesday marked a fourth day of losses for the S&P 500 and a second negative session for the Nasdaq.

    Meanwhile, the Dow Jones Industrial Average was the outlier, adding 16.04 points, or 0.04%, and settling at 44,938.31.

    — CNBC’s Yun Li, Pia Singh and Alex Harring contributed to this report.

    Continue Reading

  • Trump has bought more than $100m in bonds while president, disclosure shows | Donald Trump

    Trump has bought more than $100m in bonds while president, disclosure shows | Donald Trump

    Donald Trump has bought more than $100m in company, state and municipal bonds since taking office in January, according to new disclosures which shed further light on the vast holdings of the US’s billionaire president.

    The forms, posted online on Tuesday, show the Republican former real estate mogul made more than 600 financial purchases since 21 January, the day after he was inaugurated for his second term in the White House.

    The 12 August filing from the US Office of Government Ethics does not list exact amounts for each purchase, only giving a broad range.

    They include corporate bonds from Citigroup, Morgan Stanley and Wells Fargo, as well as Meta, Qualcomm, the Home Depot, T-Mobile USA and UnitedHealth Group.

    Other debt purchases include various bonds issued by cities, states, counties and school districts as well as gas districts, and other issuers.

    The holdings cover sectors that could benefit from US policy shifts under his administration, such as financial deregulation.

    A senior White House official said Trump continued to file mandatory disclosures about his investment portfolio but that neither he nor his family had a role in managing or selecting the bonds, which are managed by a third-party financial institution. Federal ethics officials certified the reports, which are in compliance with applicable laws, according to the official, who declined to be named.

    Trump, a businessperson turned politician, has said he has put his companies into a trust managed by his children.

    “President Trump’s net worth has increased substantially, with much of that concentrated in crypto holdings and Trump Media. Given that, there is no evidence currently that his bond purchases are anything other than a prudent diversification within his billions of dollars in assets,” said John Canavan, lead US analyst at Oxford Economics.

    “It seems like he was primarily purchasing corporate and municipal bonds and others that are high quality and highly rated, so it’s just a way to take a little bit of risk off the table,” he said.

    Trump’s annual disclosure form filed in June showed his income from various sources still ultimately accrues to the president – something that has opened him up to accusations of conflicts of interest.

    In that disclosure, which appeared to cover the 2024 calendar year, Trump reported more than $600m in income from cryptocurrencies, golf properties, licensing and other ventures. It also showed his push into crypto had added substantially to his wealth.

    Overall, Trump reported assets worth at least $1.6bn, according to a Reuters calculation at the time.

    Continue Reading

  • Treatment that can double bladder cancer survival rates available to 1,000 patients in England | Cancer

    Treatment that can double bladder cancer survival rates available to 1,000 patients in England | Cancer

    More than 1,000 patients living with bladder cancer in England will be eligible for a treatment which can double survival rates from the disease.

    In England, 18,000 people are diagnosed with bladder cancer each year, and only about 10% of people with stage 4 bladder cancer will survive five years or more after they are diagnosed.

    The treatment, enfortumab vedotin with pembrolizumab, has been approved for use on the NHS from Thursday. About 1,250 patients across the country to be offered the therapy, which has been described by NHS bosses as one of the “most hopeful advances in decades”.

    Clinical trials of the drug have shown that people with bladder cancer that has spread (metastasised) live up to twice as long when given the combination antibody treatment when compared with those given normal chemotherapy.

    One trial also found that almost 30% of patients had no detectable traces of cancer in their body following treatment with enfortumab vedotin and pembrolizumab, compared with only 12.5% with chemotherapy.

    Prof Peter Johnson, NHS England’s national clinical director for cancer, said that the treatment is “one of the most hopeful advances in decades for people with bladder cancer”.

    He added: “Bladder cancer is often difficult to treat once it has spread, but this new therapy is the first one in years to really help stop the disease in its tracks, and our rollout to NHS patients will make a huge difference to the lives of those affected and their families.”

    The therapy works by enfortumab vedotin directly targeting the cancer cells and killing them, while pembrolizumab, an immunotherapy drug, helps the immune system recognise and fight the remaining cancer cells.

    Life expectancy for people with bladder cancer which has metastasised is usually only just over a year, but this new therapy increased survival for people with this stage of the disease by more than one year.

    Jeannie Rigby, the chief executive of Action Bladder Cancer UK, said the charity, “bladder cancer patients and their families welcome this much-needed, step forward in treatments available for this hard-to-treat cancer.

    “This new drug has the potential to increase how long people have before their cancer gets worse and how long they live compared with the current, limited, treatment choices available. It’s also of importance that this treatment can mean these patients can experience a better quality of life with less hard to tolerate side effects.”

    Continue Reading